HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil

被引：101

作者：

Korkaya, Hasan ^{[1
]}

Wicha, Max S. ^{[1
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med Oncol, Ann Arbor, MI 48109 USA

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 06期

关键词：

RESISTANCE; TUMORS;

D O I：

10.1158/1078-0432.CCR-08-3087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse, suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

引用

页码：1845 / 1847

页数：3

共 12 条

[11] Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors [J].

Shafee, Norazizah ;

Smith, Christopher R. ;

Wei, Shuanzeng ;

Kim, Yoon ;

Mills, Gordon B. ;

Hortobagyi, Gabriel N. ;

Stanbridge, Eric J. ;

Lee, Eva Y-H. P. .

CANCER RESEARCH, 2008, 68 (09) :3243-3250

[12] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].

SLAMON, DJ ;

GODOLPHIN, W ;

JONES, LA ;

HOLT, JA ;

WONG, SG ;

KEITH, DE ;

LEVIN, WJ ;

STUART, SG ;

UDOVE, J ;

ULLRICH, A ;

PRESS, MF .

SCIENCE, 1989, 244 (4905) :707-712

← 1 2 →